Sumitomo dainippon pharma Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Sumitomo dainippon pharma Contact Number

Contact Us Sumitomo Dainippon Pharma

4 hours ago Ds-pharma.com Show details

Sumitomo Dainippon Pharma was established 1897, May 14. In 2005, October 1, Dainippon Pharmaceutical and Sumitomo Pharmaceuticals merged into Sumitomo Dainippon Pharma Co., Ltd. Regarding our history, please refer to.

Category: Contact SupportShow more

Contact Us Sumitomo Dainippon Pharma Oncology

2 hours ago Sdponcology.com Show details

801-285-6003Lehi, UT office. 3900 N Traverse Mountain Blvd, Suite 100. Lehi, UT 84043. 801-285-6003. SDP Oncology Inc. works together with the oncology research and development teams in Japan, DSP Cancer Institute, and Oncology Clinical Development Unit. SDP Oncology, Inc. is an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., a

Category: Contact SupportShow more

Sumitomo Dainippon Pharma

6 hours ago Ds-pharma.com Show details

Sumitomo Dainippon Pharma Announces Support for the Recommendations of the Task Force on Climate-related Financial Disclosures (TCFD) Investors Meeting Presentation for Q2 FY2021 (April 1 to September 30, 2021). Supplementary Financial Data (IFRS) …

Category: Contact NumberShow more

SUMITOMO DAINIPPON PHARMA CO., LTD. Company …

6 hours ago Dnb.com Show details

Find company research, competitor information, contact details & financial data for SUMITOMO DAINIPPON PHARMA CO., LTD. of OSAKA, OSAKA. Get …

Employees: 6.8K
Phone: 662035321
Location: 2-6-8, DOSHOMACHI, CHUO-KU, OSAKA, 541-0045, OSK

Category: Contact NumberShow more

Dainippon Sumitomo Pharma Crunchbase Company …

8 hours ago Crunchbase.com Show details

Legal Name Dainippon Sumitomo Pharma Co., Ltd. Stock Symbol TYO:4506. Company Type For Profit. Number of Exits 3. Contact Email [email protected]pharma.co.jp. Phone Number 81 6 6203 5321. "Green Prism", the symbol of Dainippon Sumitomo Pharma Co., Ltd. is a motif in the design of the "Sun"-expressing a lively sense of energy, moving on toward tomorrow

Founder: Nagayo Sensai
Location: Osaka
Founded: Jul 01, 2007

Category: Contact NumberShow more

Sumitomo Dainippon Pharma Co., Ltd. Corporate Profile

3 hours ago Ds-pharma.co.jp Show details

4 Corporate History 1 October 1, 2005 Sumitomo Dainippon Pharma created. 2006 AmBisome® (therapeutic agent for systemic fungal infection) launched. 2007 REPLAGAL® (therapeutic agent for Anderson-Fabry disease) launched. The laboratory products business was transferred to DS Pharma Biomedical Co., Ltd.

Category: Contact NumberShow more

Corporate Profile About Us Sumitomo Dainippon Pharma

2 hours ago Ds-pharma.com Show details

Sumitomo Dainippon Pharma's corporate profile. Name: Sumitomo Dainippon Pharma Co., Ltd. Establishment: May 14, 1897 : Date of merger

Category: Contact NumberShow more

Inquiry contact.dspharma.co.jp

1 hours ago Contact.ds-pharma.co.jp Show details

Sumitomo Dainippon Pharma is free to duplicate such information and materials and use them for any purpose deemed appropriate, including publication. Sumitomo Dainippon Pharma is under no obligation to respond to communications received by email or other means.

Category: Contact SupportShow more

Sumitomo Dainippon Pharma Co. , Ltd. Email Format ds

5 hours ago Rocketreach.co Show details

Sumitomo Dainippon Pharma Co. , Ltd. uses 1 email formats. The most common Sumitomo Dainippon Pharma Co. , Ltd. email format is first '-' last (ex. [email protected]pharma.co.jp) being used 100.0% of the time.. Get Verified Emails for Sumitomo Dainippon Pharma Co. , Ltd. Employees

Category: Contact NumberShow more

Christopher Katz's email & phone Sumitomo Dainippon

5 hours ago Rocketreach.co Show details

Senior Manager, Api Development @ Boston Biomedical Associate Director, Api Development @ Sumitomo Dainippon Pharma Oncology Senior Manager, Api Development @ Sumitomo Dainippon Pharma Oncology see more Contract Senior Scientist, Api Development @ Spero Therapeutics Group Leader, Process Development @ Nitto Denko Avecia Inc. Lecturer and Laboratory Director- Organic …

Category: Phone NumberShow more

Sumitomo Pharmaceuticals Asia Pacific Pte. Ltd. Overseas

2 hours ago Ds-pharma.com Show details

65-6581-8765Sumitomo Pharmaceuticals Asia Pacific Pte. Ltd. is a subsidiary established by Sumitomo Dainippon Pharma Co., Ltd. in Singapore following China as the base of its activities in the Asian region outside Japan. In April 2019, it underwent a functional reinforcement and corporate name change so that it would serve as the regional headquarters.

Business: Purchase and sales of pharmaceuticals
Telephone: +65-6581-8765
Established: January 2013

Category: Contact NumberShow more

Contact Us Sunovion Pharmaceuticals Inc.

5 hours ago Sunovion.com Show details

(866) 886-1348Compliance Hotline. If you wish to submit a report (including an anonymous report) through Sunovion’s Compliance Hotline, please contact: (866) 886-1348 or (int’l toll free) 0800-032-8483. https://sumitomodainipponpharmagroup.ethicspoint.com.

Category: Contact SupportShow more

Poxel Provides Corporate Update and Reports Cash and

3 hours ago Poxelpharma.com Show details

TWYMEEG ® (Imeglimin hydrochloride) launched in Japan on September 16 for the treatment of type 2 diabetes; Milestone payment for TWYMEEG’s approval in Japan of JPY 1.75 billion (approximately EUR 13.2 million, USD 15.8 million) 1 paid by Sumitomo Dainippon Pharma to Poxel in July 2021 Patient enrollment in PXL065 Phase 2 (DESTINY-1) trial in NASH completed in September with results

Category: Contact NumberShow more

Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter

6 hours ago Businesswire.com Show details

Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 7,000

Category: Contact NumberShow more

Sumitomo Pharmaceuticals Asia Pacific Sumitomo Chemical Asia

1 hours ago Sumitomo-chem.com.sg Show details

Sumitomo Pharmaceuticals Asia Pacific Pte. Ltd. was founded in January 2013 as a subsidiary of Sumitomo Dainippon Pharma Co., Ltd. We are dedicated to being a company of excellence for pharmaceutical products business in Southeast Asia. Currently, we are focused on obtaining approval for and marketing lurasidone hydrochloride in Southeast Asia

Category: Contact NumberShow more

News & Media Sumitomo Dainippon Pharma Oncology

9 hours ago Sdponcology.com Show details

Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on research and development for novel cancer therapeutics, today presented new findings on a range of investigational agents from the company's pipeline at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, taking place April 10-15, 2021.

Category: Contact NumberShow more

Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide

9 hours ago Otsuka.co.jp Show details

Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds. Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE), its U.S.-based subsidiary Sunovion Pharmaceuticals

Category: Contact NumberShow more

Sumitomo Dainippon Pharma and BehaVR announce landmark

4 hours ago Ih.advfn.com Show details

The treatment gap between the number of people with mental disorders and the number treated represents a major public health challenge. Sumitomo Dainippon Pharma and BehaVR believe that new approaches are needed to address these conditions, including commercializing the 20-year body of research that shows that the application of VR can be used

Category: Contact NumberShow more

Dainippon Sumitomo Pharma Funding, Financials, Valuation

7 hours ago Crunchbase.com Show details

Dainippon Sumitomo Pharma has made 8 investments. Their most recent investment was on Aug 5, 2020, when Myovant Sciences raised $200M. Dainippon Sumitomo Pharma has invested in Drawbridge Health on Aug 5, 2020. This investment - Debt Financing - Drawbridge Health - was valued at $200M. Dainippon Sumitomo Pharma has had 2 exits.

Category: Contact NumberShow more

Our Efforts Against the Novel Coronavirus dspharma.com

9 hours ago Ds-pharma.com Show details

Our Efforts Against the Novel Coronavirus Disease (COVID-19) We express our deepest sorrow for the people who passed away due to the novel coronavirus disease (COVID-19). We also extend our sincerest condolences to the bereaved families, and our heartfelt sympathies to those who are suffering from or affected by the disease.

Category: Contact NumberShow more

Sumitomo Dainippon Pharma and BehaVR announce landmark

6 hours ago Wfmz.com Show details

Sumitomo Dainippon Pharma's wholly-owned US subsidiary, Sunovion Pharmaceuticals Inc. and BehaVR, signed an initial collaboration agreement in June 2020 to co-develop a wellness product for those

Category: Contact NumberShow more

Corporate Responsibility Sumitomo Dainippon Pharma Oncology

9 hours ago Sdponcology.com Show details

Sumitomo Dainippon Pharma Oncology aims to make a difference in the lives of both patients with cancer and the community. Learn about our commitment to supporting and understanding the needs of patients and families living with cancer.

Category: Contact NumberShow more

Mahmoud Mahmoudian at Sumitomo Dainippon Pharma …

5 hours ago Arounddeal.com Show details

Senior Vice President, Head of Global Oncology External Innovation at Sumitomo Dainippon Pharma Oncology. Mahmoud Mahmoudian is the Senior Vice President, Head of Global Oncology External Innovation at Sumitomo Dainippon Pharma Oncology based in United States.Entrepreneurial C-level PhD Biotech Executive with global R&D, VENTURE, BUSINESS …

Category: Contact NumberShow more

Sumitomo Dainippon Pharma Wikipedia

5 hours ago En.wikipedia.org Show details

Another origin of the company is Sumitomo Pharmaceuticals, incorporated in 1984 as a subsidiary of Sumitomo Chemical (holding 77.83% of the share as of 2006). Dainippon and Sumitomo merged on October 1, 2005 to create Dainippon Sumitomo Pharma. As a result, Sumitomo Chemical has 50.20% ownership in Dainippon Sumitomo Pharma as of March 31, 2014.

Category: Contact NumberShow more

SUMITOMO DAINIPPON PHARMA CO., LTD. : Shareholders Board

5 hours ago Marketscreener.com Show details

Sumitomo Dainippon Pharma Co., Ltd., is a pharmaceutical company. The Company operates in four segments. The Japan segment manufactures and sells medical drugs.

Category: Contact NumberShow more

Dainippon Sumitomo Pharma Co. Ltd. Sunovion

Just Now Lawyers.findlaw.com Show details

Dainippon Sumitomo Pharma Co. Ltd. (Main Office) 2-6-8 Doshomachi, Chuo-ku Osaka 541-0045 , Japan +81-6-6203-5321 . Dainippon Sumitomo Pharma Co. Ltd. - Sunovion Pharmaceuticals Inc. (Branch Office) One Bridge Plaza Suite 510 Fort Lee, NJ 07024

Category: Contact NumberShow more

Sumitomo Dainippon Pharma Oncology Announces First Patient

1 hours ago Markets.businessinsider.com Show details

Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 7,000

Category: Contact NumberShow more

Sumitomo Dainippon Pharma Co., Ltd. Share Price Trade now

4 hours ago Capital.com Show details

The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. Sumitomo Dainippon Pharma Co., Ltd. was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Category: Contact NumberShow more

Sumitomo Dainippon Pharma : Discovering and designing

8 hours ago Marketscreener.com Show details

In a landmark development, the first drug created using artificial intelligence (AI) has moved into its Phase I trial. Named DSP-1181, the compound was created in a joint venture between Exscientia and Sumitomo Dainippon Pharma for the treatment of obsessive-compulsive disorder (OCD).. Speaking with Drug Target Review's Victoria Rees, Professor Andrew Hopkins, Chief …

Category: Contact NumberShow more

Supplementary Financial Data (IFRS) for the Second Quarter

8 hours ago Marketscreener.com Show details

October 27, 2021 Sumitomo Dainippon Pharma Co., Ltd. This material contains forecasts, projections, targets, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the …

Category: Contact NumberShow more

Sumitomo Dainippon Pharma and BehaVR announce landmark

8 hours ago Markets.businessinsider.com Show details

703-989-0014Media Contacts: Sumitomo Dainippon Pharma Co., Ltd. Corporate Communications TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)BehaVR Rory Channer [email protected] 703-989-0014

Category: Contact NumberShow more

Submit Medical Inquiry Sunovion Medical

4 hours ago Sunovionmedical.com Show details

877-737-7226Submit Medical Inquiry. Please do not provide any patient identifiable information in accordance with privacy laws and Sunovion policies, including but not limited to HIPAA. To report an Adverse Event call 1-877-737-7226. To report a Product Complaint call 1-866-468-1701. Thank you for your interest in Sunovion Pharmaceuticals Inc.

Category: Contact NumberShow more

Home Sunovion Medical

2 hours ago Sunovionmedical.com Show details

sunovion pharmaceuticals mission: to broadly contribute to society through value creation based on innovative research and development activities for the betterment of health care and …

Category: Home PhoneShow more

Nobuhiko Tamura, Chairman & Chief Executive Officer at

2 hours ago Relationshipscience.com Show details

Sumitomo Dainippon Pharma Co., Ltd. engages in manufacture, sale, import, and export of pharmaceutical products. It operates through the Pharmaceutical Business and Other Business segments. The Pharmaceutical Business segment manufactures and sells generic and prescription drugs in Japan, North America, China, and other overseas countries .

Category: Contact NumberShow more

Sunovion Pharmaceuticals Inc. Sunovion Pharmaceuticals

3 hours ago News.sunovion.com Show details

Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has about 7,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at www.ds-pharma.com. BROVANA is a

Category: Contact NumberShow more

Corporate Profile November 2021 MarketScreener

4 hours ago Marketscreener.com Show details

The approval in Japan triggered EUR 13.5 million loan from IPF in June 2021 and a milestone payment of EUR 13.2 million (USD 15.8 million) 2 from Sumitomo Dainippon Pharma received in July 2021 Sumitomo Dainippon Pharma product launch in Japan in September 2021; Sumitomo Dainippon Pharma #1 diabetes franchise in Japan; FY20 USD 890 million 3

Category: Contact NumberShow more

SUMITOMO DAINIPPON PHARMA CO., LTD. : 4506 Stock Price

7 hours ago Marketscreener.com Show details

Sumitomo Dainippon Pharma Co., Ltd., is a pharmaceutical company. The Company operates in four segments. The Japan segment manufactures and sells medical drugs. The North America segment manufactures, develops, purchases and sells ethical drugs. The China segment manufactures and sells ethical drugs through its consolidated subsidiary.

Category: Contact NumberShow more

Working at Sumitomo Dainippon Pharma Glassdoor

1 hours ago Glassdoor.com Show details

Company - Public (45060) Industry: Chemical Manufacturing. Revenue: $2 to $5 billion (USD) Competitors: UNKNOWN. Healthy bodies, healthy lives," is the goal of Dainippon Sumitomo Pharma (DSP). Through research and development, the Japanese drugmaker produces a wide range of therapeutics in such categories as cardiovascular disease

Category: Contact NumberShow more

Sumitomo Dainippon Pharma and BehaVR announce landmark

6 hours ago Pharmafocusasia.com Show details

Sumitomo Dainippon Pharma and BehaVR announce landmark deal for multiple virtual reality digital therapeutics. Tuesday, October 19, 2021 . Sumitomo Dainippon Pharma Co., Ltd., and BehaVR, Inc., announce today that the companies have signed definitive agreements to develop and commercialize both prescription digital therapeutics and general wellness products for treatment of …

Category: Contact NumberShow more

Sumitomo Dainippon Pharma and BehaVR announce landmark

7 hours ago Kfyrtv.com Show details

703-989-0014Media Contacts: Sumitomo Dainippon Pharma Co., Ltd. Corporate Communications TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo) BehaVR Rory Channer [email protected] 703-989-0014 References

Category: Contact NumberShow more

A Study of DSP5336 in Relapsed/Refractory AML/ ALL With

7 hours ago Clinicaltrials.gov Show details

Sumitomo Dainippon Pharma Oncology, Inc: ClinicalTrials.gov Identifier: NCT04988555 Other Study ID Numbers: DSP-5336-101 : First Posted: August 3, 2021 Key Record Dates: Last Update Posted: October 7, 2021 Last Verified: September 2021 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD:

Category: Contact NumberShow more

Sumitomo Dainippon Pharma Oncology, Inc. Website Privacy

5 hours ago Sdponcology.com Show details

both Sumitomo Dainippon Pharma Oncology, Inc.’s online and offline activities. For more information about how we collect , use, and share information through our websites and online services, please review our number or subscriber identification number, any unique identifier used by a Contact Us Call + 1 -833- 661 -0093 or submit a form :

Category: Contact NumberShow more

Directors Altavant

9 hours ago Altavant.com Show details

Bill Symonds, PharmD

Category: Contact NumberShow more

Nashville Inno Nashvillebased BehaVR inks potential

9 hours ago Bizjournals.com Show details

The deal, with Osaka-based Sumitomo Dainippon Pharma Co., is for the companies to develop and commercialize prescription digital therapies …

Category: Contact NumberShow more

EX2.1

2 hours ago Sec.gov Show details

WHEREAS, as a condition and inducement to the Company’s willingness to enter into this Agreement, Sumitomo is entering into this Agreement solely to provide the guaranty, make the representations and agree to the covenants set forth in Section 9.13 in favor of the Company; and . WHEREAS, the Company, Parent and Merger Sub desire to make certain representations, warranties, covenants, and

Category: Contact NumberShow more

Search Medical Information Sunovion Medical

3 hours ago Sunovionmedical.com Show details

I confirm that I am a Health Care Professional (HCP) practicing in the United States, or acting on behalf of an HCP

Category: Contact NumberShow more

Poxel Provides Corporate Update and Reports Cash and

9 hours ago Sharewise.com Show details

In a lesser extent, it also included an allocated portion of the EUR 36.0 million upfront payment received from Sumitomo Dainippon Pharma relating to the strategic corporate partnership announced on October 30, 2017, as well as the residual Imeglimin Phase 3 program costs in Japan incurred during the first nine months of 2020 that were re

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

Where is the headquarters of Sumitomo Dainippon Pharma?

Sumitomo Dainippon Pharma Co., Ltd. (大日本住友製薬株式会社, Dainippon Sumitomo Seiyaku Kabushiki-Gaisha) is a pharmaceutical company based in Japan. Its headquarters are in Chuo-ku, Osaka.

When was Sunovion acquired by Sumitomo Dainippon?

Sunovion (formerly Sepracor Inc.), was acquired by Sumitomo Dainippon in 2010, is a subsidiary now based in Marlborough, Massachusetts, USA. In September 2016, the Sunovion announced it would acquire Cynapsus Therapeutics for approximately $624 million, specifically expanding Sunovion's central nervous system drug portfolio.

Is there a Sumitomo pharmaceutical company in Australia?

Further in the future, Sumitomo Pharmaceuticals Asia Pacific Pte. Ltd. will expand its product lineups in Southeast Asia and pursue business expansion into neighboring countries such as Australia.

Who was the founder of Dainippon Pharma Company?

The original Dainippon Pharmaceuticals (Dainippon Seiyaku) was established in 1885 by Nagayo Sensai, a graduate of Tekijuku – the first private medical school in Japan established by Ogata Kōan. It was set up as a wholly private company invested by a number of people in Tokyo and Osaka, with the land and buildings let by the government.

Popular Brands

Sharp
Shell
Sap
Sgs
Sabb
Sea